Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years

Asthma (in children) - corticosteroids: Review Decision - February 2013 information

Asthma (in children) - corticosteroids: Appendix A - decision paper presented to the Institute's Guidance Executive (PDF 147 KB)

TA131 Asthma (in children) - corticosteroids: review proposal - November 2012 information

TA131 Asthma (in children) - corticosteroids: appendix A - provisional matrix of stakeholders (PDF 33 KB)

TA131 Asthma (in children) - corticosteroids: appendix B - proposal paper presented to the Institute's Guidance Executive (PDF 342 KB)

Asthma in (children) - corticosteriods: (final appraisal determination)

Asthma in children - corticosteriods: Final appraisal determination information

Asthma in children - corticosteriods: Final appraisal determination (PDF 129 KB)

Response to consultee, commentator and public comments on the ACD and comments from website consultation (PDF 151 KB)

Ms Sally Rose, Patient Expert nominated by Asthma UK (PDF 7.9 KB)

Consultee and commentator comments on the ACD

AstraZeneca (PDF 97 KB)

GlaxoSmithKline (PDF 90 KB)

British Paediatric Respiratory Society (PDF 27 KB)

General Practice Airway Group (PDF 40 KB)

Royal College of Nursing (PDF 22 KB)

Department of Health (PDF 8.6 KB)

Asthma and Allergy Research Group (PDF 13 KB)

NHS Quality Improvement Scotland (PDF 15 KB)

Asthma in children - corticosteriods: Appraisal Consultation Document information

Evaluation report

Assessment report (PDF 1.42 MB)

Addendum to the Assessment report (PDF 134 KB)

Consultee and commentator comments on the Assessment report

Manufacturers

AstraZeneca (PDF 39 KB)

GlaxoSmithKline UK (PDF 95 KB)

Meda Pharmaceuticals Ltd (PDF 36 KB)

Trinity - Chiesi Pharmaceuticals Ltd (PDF 34 KB)

Patient and Professional group

Action against Allergy (PDF 25 KB)

British Paediatric Respiratory Society (PDF 14 KB)

General Practice Airways Group (GPIAG) 1 (PDF 45 KB)

General Practice Airways Group (GPIAG) 2 (PDF 200 KB)

Royal College of Paediaticians (PDF 41 KB)

Napp Pharmaceuticals Ltd (PDF 10 KB)

Response to Consultees comments on the Assessment report (PDF 102 KB)

Non-manufacturer submissions

Action for Sick Children (PDF 16 KB)

British Lung Foundation (PDF 28 KB)

British Thoracic Society (PDF 11 KB)

Education for Health 1 (PDF 56 KB)

Education for Health 2 (PDF 91 KB)

General Practice Airways Group 1 (PDF 23 KB)

General Practice Airways Group 2 (PDF 147 KB)

Royal College of Physicians of Edinburgh (PDF 30 KB)

Manufacturer submissions (executive summary only)

AstraZeneca (PDF 80 KB)

GSK (PDF 117 KB)

Meda Pharmaceuticals Ltd (PDF 31 KB)

Trinity Chiesi (PDF 41 KB)

Expert written personal statements

Jonathan Grigg (PDF 11 KB)

Mike Thomas (PDF 25 KB)

Sally Rose (PDF 30 KB)

Asthma (in children) - corticosteroids: Final protocol (PDF 119 KB)

Asthma (children under 12) - Final scope (PDF 42 KB)

Summary of consultee and commentator comments on the draft scope (PDF 94 KB)

Summary of consultee and commentator comments on the provisional matrix (PDF 15 KB)

Archive: Asthma (children under 12) - Draft scope (PDF 46 KB)

Archive: Asthma (children under 12) - Provisional Matrix (PDF 38 KB)